Baseline Patient and Treatment Characteristics
| Characteristic | Data |
| Sex | |
| Male | 25 (62.5) |
| Female | 15 (37.5) |
| Age (y) | 64 (37–84) |
| World Health Organization performance score | |
| 0 | 28 (70) |
| 1 | 11 (27.5) |
| 2 | 1 (2.5) |
| Previous locoregional (liver) therapy* | |
| External-beam radiation therapy | 2 (5) |
| Metastasectomy | 5 (12.5) |
| Radiofrequency ablation | 3 (7.5) |
| Lines of prior systemic treatment | |
| 1 | 8 (20) |
| 2 | 20 (50) |
| 3 | 7 (17.5) |
| 4 | 5 (12.5) |
| Extrahepatic disease before treatment | |
| Lymph node | 10 (25) |
| Lung | 10 (25) |
| No | 23 (57.5) |
| Liver volume (cm3) | 1,987 (1,272–3,167) |
| Metabolic tumor volume (cm3) | 320 (26–1,446) |
| Fractional tumor load | 0.15 (0.01–0.49) |
| Radioembolization treatment | |
| Whole-liver | 39 (97.5) |
| Lobar (right lobe only) | 1 (2.5) |
| Administered activity (MBq) | 6,387 (3,822–12,386) |
↵* No patient received synchronous systemic treatment.
Qualitative data are numbers and percentages; continuous data are median and range.